Molbio Diagnostics Limited (NSE: MOLBIO, BSE: 544866) is a Verna, Goa-based company in the Medical Testing, Analyzing, and Diagnostic Equipment industry. With a market capitalisation of ₹15,144 Cr, it ranks #433 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 7 in Medical Testing, Analyzing, and Diagnostic Equipment. At ₹1,333.80 (as of 9 Nov 2026), the share price is 20.9% below its 52-week high of ₹1,686.80 and 44.0% above its 52-week low of ₹926.35.
| Current Price | ₹1,333.80 |
|---|---|
| Market Cap | ₹15,144 Cr |
| NSE Symbol | MOLBIO |
| BSE Code | 544866 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies |
| Sub-Industry | Health Care Equipment > Medical Testing, Analyzing, and Diagnostic Equipment |
| P/E Ratio | 89 |
| Return on Assets | 9.24% |
| 52-Week Range | ₹926.35 – ₹1,686.80 |
| Beta (1Y) | -0.17 |
| Headquarters | Verna, Goa |
| Website | www.molbiodiagnostics.com |
| Revenue | ₹259 Cr |
|---|---|
| Net Profit | ₹8 Cr |
| Net Margin | 3.0% |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 41.29% of Molbio Diagnostics Limited's shares as of Sept 2026, unchanged from Aug 2026. Delivery averaged 19.6% of traded volume across 16 NSE sessions (15 Oct 2026 – 9 Nov 2026).
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Ve
1. Diagnostic Kits / Equipment-This segment provides healthcare technologies to diagnose infectious and non-communicable diseases. 2. NA-NA 3. NA-NA 4. NA-NA
1. Diagnostic Kits / Equipment-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Molbio Diagnostics Limited | ₹15,144 Cr | 89 | — | ₹259 Cr | — |
| Hemant Surgical Industries Lim | ₹850 Cr | 39.1 | — | — | +120.8% |
| Credent Connect N Care | ₹728 Cr | 28.6 | — | — | — |
| QMS Medical Allied Services Limited | ₹333 Cr | 31.9 | 12.29% | ₹57 Cr | +76.8% |
| Nureca Ltd | ₹285 Cr | 141.5 | 1.11% | ₹59 Cr | +18.2% |
| Avience Biomedicals Limited | ₹134 Cr | 11.3 | 27.86% | — | — |
| Earkart Limited | ₹0 Cr | 29.1 | — | ₹0 Cr | -53.1% |
Listed by market capitalisation. Ratios are shown for context only.
Molbio Diagnostics Limited is trading at ₹1,333.80, with a market capitalisation of ₹15,144 Cr.
Molbio Diagnostics Limited operates in the Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies space (Health Care Equipment > Medical Testing, Analyzing, and Diagnostic Equipment).
Molbio Diagnostics Limited has a P/E of 89.
Molbio Diagnostics Limited is listed on the NSE under the symbol MOLBIO and on the BSE under the scrip code 544866.
In Q2 FY27, Molbio Diagnostics Limited reported revenue of ₹259 Cr and net profit of ₹8 Cr (consolidated, parsed from the company's exchange filing).
Promoters held 41.29% of Molbio Diagnostics Limited's shares as of Sept 2026, unchanged from Aug 2026.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.